Invitae’s PCM Assay for Minimal Residual Disease Receives its First Commercial Coverage

– Blue Shield of California has over 3 million covered members in CA – SAN FRANCISCO, March 6, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that its Personalized Cancer Monitoring (PCM™) assay, which helps detect minimal residual disease...

Click to view original post